Compare IPW & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPW | BBLG |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Catalog/Specialty Distribution | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1M | 1.2M |
| IPO Year | 2021 | 2014 |
| Metric | IPW | BBLG |
|---|---|---|
| Price | $0.40 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 50.8K |
| Earning Date | 10-02-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.13 |
| EPS | N/A | ★ N/A |
| Revenue | $19,956,938.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $596.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $0.38 |
| 52 Week High | $4,092,187,400.00 | $5.20 |
| Indicator | IPW | BBLG |
|---|---|---|
| Relative Strength Index (RSI) | 24.74 | 16.96 |
| Support Level | N/A | N/A |
| Resistance Level | $1.57 | $1.18 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | 34.28 | 0.01 |
| Stochastic Oscillator | 4.85 | 18.11 |
iPower Inc is a technology-enabled commerce infrastructure company providing supply chain, logistics, fulfillment, warehousing and procurement solutions for e-commerce and distribution channels. Its product portfolio includes hydroponic products, gardening supplies, home goods and related accessories, with gardening and home products. Geographically, the company generates majority of its revenue from the United States, followed by Canada and other international markets.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.